Syndax Pharmaceuticals, Inc. (SNDX)
| Market Cap | 844.13M |
| Revenue (ttm) | 1.52M |
| Net Income (ttm) | -89.55M |
| Shares Out | 51.50M |
| EPS (ttm) | -1.88 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 13 |
| Last Price | $18.11 |
| Previous Close | $17.92 |
| Change ($) | 0.19 |
| Change (%) | 1.06% |
| Day's Open | 17.85 |
| Day's Range | 16.87 - 18.54 |
| Day's Volume | 702,426 |
| 52-Week Range | 13.02 - 27.85 |
Syndax Pharmaceuticals Inc (NASDAQ: SNDX), in its Q1 earnings, also announced new data from the ongoing Phase 1 dose-escalation portion of the Phase 1/2 AUGMENT-101 trial evaluating SNDX-5613 in patient...
Shares of Syndax Pharmaceuticals (NASDAQ:SNDX) rose in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 3.57% year over year to ($0.54), which bea...
WALTHAM, Mass., May 11, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline o...
WALTHAM, Mass., May 4, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of...
Syndax (SNDX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
The company announced results from an early-stage clinical study.
CRISPR Therapeutics AG (NASDAQ: CRSP), Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) and KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) were among the early movers in the biopharma space Tuesday. CRISPR Ri...
WALTHAM, Mass., April 20, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline ...
WALTHAM, Mass., April 15, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline ...
The FDA grants orphan drug designation to Syndax's (SNDX) axatilimab for the treatment of patients with idiopathic pulmonary fibrosis. Shares up.
WALTHAM, Mass., April 8, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline ...
The FDA bestows an orphan drug designation on Syndax's (SNDX) axatilimab for the treatment of patients with chronic graft versus host disease. Shares up.
WALTHAM, Mass., March 31, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline...
Shares of Syndax Pharmaceuticals (NASDAQ:SNDX) were flat in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 0.00% year over year to ($0.44), wh...
WALTHAM, Mass., March 8, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline ...
WALTHAM, Mass., Dec. 18, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline ...
Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company focused on a 2-product pipeline including SNDX-5613, a Menin inhibitor for MLLR/NPM1, and SNDX-6352, a monoclonal antibody for GVHD.
WALTHAM, Mass., Dec. 9, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline o...
WALTHAM, Mass., Dec. 7, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline o...
Investors need to pay close attention to Syndax Pharmaceuticals (SNDX) stock based on the movements in the options market lately.
WALTHAM, Mass., Dec. 6, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline o...
WALTHAM, Mass., Nov. 30, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline ...
WALTHAM, Mass., Nov. 11, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline ...
Syndax Pharmaceuticals, Inc. (SNDX) CEO Briggs Morrison on Q3 2020 Results - Earnings Call Transcript
Syndax Pharmaceuticals, Inc. (SNDX) CEO Briggs Morrison on Q2 2020 Results - Earnings Call Transcript
WALTHAM, Mass., Aug. 6, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc.
Syndax's Latest Data Disappoints, But The True Value Lies With SNDX-5613 And SNDX-6352
Syndax Pharmaceuticals stock tumbled to a month-low Friday after the biotech's breast cancer treatment failed in a Phase 3 test. Syndax says it won't be asking for FDA approval.
WALTHAM, Mass., May 21, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX) today announced receipt of the final results of E2112, the Phase 3 clinical trial conducted by ECOG-ACRIN Cancer ...
Syndax Pharmaceuticals, Inc. (SNDX) CEO Briggs Morrison on Q1 2020 Results - Earnings Call Transcript
Syndax (SNDX) delivered earnings and revenue surprises of -9.80% and -0.26%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Initial data from an early-stage leukemia trial is promising.
Shares of Syndax Pharmaceuticals soared to a record high Tuesday after the biotech company unveiled promising results for its early-stage blood cancer treatment in leukemia patients. The post Why This ...
Syndax (SNDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
As of late, it has definitely been a great time to be an investor in Syndax Pharmaceuticals.
Syndax Pharmaceuticals, Inc. (SNDX) CEO Briggs Morrison on Q4 2019 Results - Earnings Call Transcript
Syndax (SNDX) delivered earnings and revenue surprises of 4.35% and 0.00%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
As of late, it has definitely been a great time to be an investor Syndax Pharmaceuticals, Inc. (SNDX).
Syndax Pharmaceuticals, Inc. (SNDX) CEO Briggs Morrison on Q3 2019 Results - Earnings Call Transcript
Syndax (SNDX) delivered earnings and revenue surprises of 14.58% and -0.26%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Syndax (SNDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Needless to say, the biotech world has had a difficult 2019, with the SPDR S&P Biotech ETF (NYSE: XBI) down 20% from highs posted in April.
Investors need to pay close attention to Syndax (SNDX) stock based on the movements in the options market lately.
Syndax Pharmaceuticals, Inc. (SNDX) CEO Briggs Morrison on Q2 2019 Results - Earnings Call Transcript
Syndax (SNDX) delivered earnings and revenue surprises of -6.82% and -2.82%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Syndax (SNDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Syndax Pharmaceuticals' (SNDX) CEO Briggs Morrison on Q1 2019 Results - Earnings Call Transcript
About SNDX
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic ... [Read more...]
| Industry Biotechnology | IPO Date Mar 3, 2016 |
| CEO Arlene Morris | Employees 43 |
| Stock Exchange NASDAQ | Ticker Symbol SNDX |
Financial Performance
In 2020, SNDX's revenue was $1.52 million, a change of 0.00% compared to the previous year's $1.52 million. Losses were -$77.06 million, 37.5% more than in 2019.
Analyst Forecasts
According to 7 analysts, the average rating for SNDX stock is "Strong Buy." The 12-month stock price forecast is 28.60, which is an increase of 57.92% from the latest price.